Megakaryocyte growth factors and acute myeloid leukemia
TO THE EDITOR I read with interest the review paper by Hofmann and colleagues 1 on the potential role of megakaryocytic growth factors in patients with thrombocytopenia. Overall, the authors nicely summarize a very rapidly growing literature in the field, and bring several important questions to the fore. However, I believe the wrong impression is left in their discussion of the effects of thrombopoietin in patients undergoing standard dose chemotherapy for acute myelogenous leukemia. On this topic Hofmann and colleagues cite an abstract submitted to the 1996 meeting of the American Society of Hematology, 2 and suggest that thrombopoietin had a favorable effect on platelet recovery (22 days to unsupported platelet count у20 000/l in the two thrombopoietin treatment groups vs 27 days in the placebo group). Although the printed abstract clearly provides these data, when the study group had doubled in size by the time the paper was presented in December 1996, the favorable differences between the treatment and placebo groups disappeared, and the lead author, Dr Archimbaud, concluded there was no effect of thrombopoietin when given to their patients In our review, which is based on a lecture delivered in July 1997 at the XIX Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (Mannheim, Germany), we describe a multicenter study of PEG-rHuMGDF in patients with de novo AML, and cite the abstract that was submitted to -and presented at -the 1996 meeting of the American Society of Hematology. What is described in the review is the comparison between the MGDF and placebo groups in terms of platelet recovery times, incidence of thrombocytosis, prolonged elevations of platelet counts, days to neutrophil recovery, RBC transfusion requirements, incidence of thrombotic events and remission rates as provided in this abstract. Already at this ASH meeting, the lead author Dr Archimbaud showed on the basis of a somewhat larger number of patients that the difference in thrombocytopenia duration between the placebo and MGDF groups was diminished, whereas the other observations were essentially as stated in the abstract and described in our paper. Since none of the results of this study were, to our knowledge, available in any published form, we therefore felt it was appropriate to refer to this abstract, a decision that is open to debate. Dr Archimbaud's conclusion in his presentation at the 1996 ASH meeting was not that MGDF had no effect in patients with AML, but that the apparent lack of clinical benefit in terms of time to platelet recovery and platelet transfusion requirements could possibly be attributed to insufficient scheduling. This assumption also provided the rationale for the subsequent study of PEG-rHuMGDF which was ongoing at the time our review was being written. Accordingly, in our conclusions we did not attribute a beneficial clinical effect to MGDF application but instead discussed the necessity of further studies dealing particularly with issues of pharmocokinetics and scheduling. We therefore do not consider our interpretations to be misleading.
In the meantime, the above-mentioned study has been completed and, while showing a biological effect of MGDF in terms of stimulating platelet production, it demonstrates no difference in the incidence or duration of thrombocytopenia and no reduction of platelet transfusion requirements. A manuscript summarizing the results of this clinical trial has been submitted for publication.
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